Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of the Combination of Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Relapsed Hodgkin Lymphoma (HL) and B-Non-Hodgkin- Lymphoma (B-NHL)

NCT06484920 is registered in ClinicalTrials.gov with Rita Assi as lead sponsor.

NCT NCT06484920
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06484920 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of the Combination of Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Relapsed Hodgkin Lymphoma (HL) and B-Non-Hodgkin- Lymphoma (B-NHL)
Lead sponsor
Rita Assi
Phase
Phase 2
Overall status
Recruiting
Start date
November 18, 2024
Completion date
September 30, 2029
Enrollment
24 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell lymphoma, refractory hodgkin lymphoma, refractory non-hodgkin lymphoma, relapsed hodgkin lymphoma, relapsed non-hodgkin lymphoma